MedTrace Logo

Non-Interventional Study on the Tolerability and Efficacy of IVIG

NCT02303093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 344

Last updated 2021-06-29

Study results available
· View outcomes & findings →

Summary

Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%

Conditions

  • Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

Interventions

BIOLOGICAL

Octagam IVIG 5% or 10%

Octagam IVIG 5% or 10%

BIOLOGICAL

Panzyga

Panzyga

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Lidia Cosentino · Octapharma

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-01
Primary Completion
2020-06-05
Completion
2020-06-05
FDA Drug
Yes

Countries

  • Austria
  • Canada
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303093 on ClinicalTrials.gov